Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Trastuzumab 25Carboplatin 20Paclitaxel 19pertuzumab 18pyrotinib 17Cyclophosphamide 17Capecitabine 16trastuzumab deruxtecan 15Docetaxel 15Radiotherapy 13Standard of Care 12Fulvestrant 12Drug Therapy 12dalpiciclib 11Letrozole 11pembrolizumab 9Epirubicin 9sacituzumab govitecan 8palbociclib 8exemestane 8eribulin 8Anastrozole 8Injections 7Doxorubicin 7130-nm albumin-bound paclitaxel 7toripalimab 6abemaciclib 6Tamoxifen 6Specimen Handling 6Neoadjuvant Therapy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × pirfenidone × Breast × Clear all
NCT07161791 2025-09-09

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

Harbin Medical University

Phase 1/2 Not yet recruiting
12 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡